Eli Lilly Free Cash Flow 2012-2026 | LLY

Eli Lilly annual/quarterly free cash flow history and growth rate from 2012 to 2026. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
  • Eli Lilly free cash flow for the quarter ending March 31, 2026 was 0.00, a year-over-year.
  • Eli Lilly free cash flow for the twelve months ending March 31, 2026 was , a year-over-year.
  • Eli Lilly annual free cash flow for 2025 was $0B, a 100% decline from 2024.
  • Eli Lilly annual free cash flow for 2024 was $3.76B, a 374.46% increase from 2023.
  • Eli Lilly annual free cash flow for 2023 was $0.793B, a 86.17% decline from 2022.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Eli Lilly Annual Free Cash Flow
2025
2024 3,760.10
2023 792.50
2022 5,731.40
2021 6,056.10
2020 5,111.70
2019 3,802.70
2018 4,313.90
2017 4,538.80
2016 3,887.40
2015 1,991.00
2014 3,311.10
2013 4,902.30
2012 4,421.40
2011 6,587.80
Eli Lilly Quarterly Free Cash Flow
2025-12-31
2025-09-30 8,294.10
2025-06-30 1,545.90
2025-03-31 156.10
2024-12-31 3,760.10
2024-09-30 2,782.30
2024-06-30 421.10
2024-03-31 179.70
2023-12-31 792.50
2023-09-30 2,175.00
2023-06-30 955.80
2023-03-31 1,062.10
2022-12-31 5,731.40
2022-09-30 4,569.40
2022-06-30 2,969.90
2022-03-31 2,157.60
2021-12-31 6,056.10
2021-09-30 4,085.80
2021-06-30 2,791.30
2021-03-31 1,397.10
2020-12-31 5,111.70
2020-09-30 3,751.20
2020-06-30 2,337.70
2020-03-31 124.10
2019-12-31 3,802.70
2019-09-30 2,165.50
2019-06-30 918.80
2019-03-31 107.60
2018-12-31 4,313.90
2018-09-30 3,259.50
2018-06-30 1,407.50
2018-03-31 200.00
2017-12-31 4,538.80
2017-09-30 3,238.80
2017-06-30 1,600.40
2017-03-31 170.90
2016-12-31 3,887.40
2016-09-30 2,217.30
2016-06-30 783.10
2016-03-31 -373.40
2015-12-31 1,991.00
2015-09-30 1,282.50
2015-06-30 451.30
2015-03-31 -273.40
2014-12-31 3,311.10
2014-09-30 2,263.70
2014-06-30 869.30
2014-03-31 70.30
2013-12-31 4,902.30
2013-09-30 3,460.10
2013-06-30 1,722.30
2013-03-31 221.50
2012-12-31 4,421.40
2012-09-30 3,210.60
2012-06-30 1,848.30
2012-03-31 721.80
2011-12-31 6,587.80
2011-09-30 4,873.70
2011-06-30 2,976.00
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $887.629B $65.179B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $574.358B 22.08
AbbVie (ABBV) United States $367.673B 20.79
Roche Holding AG (RHHBY) Switzerland $318.782B 0.00
Merck (MRK) United States $299.893B 13.54
Novartis AG (NVS) Switzerland $293.951B 17.16
Novo Nordisk (NVO) Denmark $167.527B 9.60
Pfizer (PFE) United States $153.074B 8.33
Sanofi (SNY) France $114.048B 10.56
Bayer (BAYRY) Germany $46.178B 8.70
Innoviva (INVA) United States $1.760B 5.88